Evommune Stock

Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.

Sign up today and learn more about Evommune Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Evommune Stock

Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed at combating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles.

Funding History

November 2020$12.5M
September 2021$83.0M
April 2023$50.0M


Co-Founder & Chief Medical Officer

Eugene A. Bauer

Chief Corporate Strategy and Legal Officer

Greg Moss

SVP, Product Development

Janice Drew

Chief Scientific Officer

Jeegar Patel

Senior Vice President Research

Hans Hofland

Founder, President & CEO

Luis Pena


Ben McGraw


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: